Cardiotoxicity related to intrapericardial infusion of bevacizumab in the treatment of lung cancer-mediated malignant pericardial effusion: a case report.

Background: Lung cancer can result in malignant pericardial effusion (MPE), impacting patient prognosis. Intrapericardial infusion of bevacizumab was an alternative treatment for MPE. Case presentation: We present the case of a 48-year-old female with stage IV lung adenocarcinoma and MPE. MPE was managed by intrapericardial infusion of bevacizumab. The first intrapericardial infusion of bevacizumab effectively controlled the MPE for 8 months. Cardiotoxicity quickly emerged after the second intrapericardial infusion of bevacizumab. After intensive treatment, the symptoms of cardiotoxicity resolved within 10 days. Conclusion: The present case indicates that intrapericardial infusion of bevacizumab could lead to cardiotoxicity in MPE patient. Cardiac examinations should be conducted before and after anti-vascular endothelial growth factor treatment.